ENTROPY NEURODYNAMICS LIMITED — Capital/Financing Update 2020

Aug 20, 2020

Market Announcement

==> picture [33 x 50] intentionally omitted <==

21 August 2020

==> picture [451 x 5] intentionally omitted <==

Exopharm Limited (ASX: EX1) – Trading Halt (2+2)

Description

The securities of Exopharm Limited (‘EX1’) will be placed in trading halt at the request of EX1, pending it releasing an announcement regarding a capital raising. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 28 August 2020 or when the announcement is released to the market.

Issued by

Sean Maloney

Adviser, Listings Compliance (Perth)

Market Announcement 1/1 ASX Customer Service Centre 131 279 | asx.com.au

21 August 2020 ASX Limited

==> picture [595 x 78] intentionally omitted <==

21 August 2020

Australian Securities Exchange Limited Level 40, Central Park 152-158 St George’s Terrace Perth WA 6000

By email: tradinghaltsperth@asx.com.au

REQUEST FOR TRADING HALT

Pursuant to ASX Listing Rule 17.1, Exopharm Limited (the “Company”) requests immediate back-to-back trading halts on its securities (ASX:EX1).

In accordance with Listing Rule 17.1, the Company advises that:

1. The back-to-back trading halts are requested pending the release of an announcement regarding a capital raising;

2. The Company requests that the back-to-back trading halts remain in place until the earlier of the commencement of trade on Friday 28 August 2020 or the release of an announcement by the Company in respect of the capital raising; and

3. The Company is not aware of any reason the back-to-back trading halts should not be granted or any other information necessary to inform the market about the trading halts.

This request has been authorised by the Board of Exopharm Limited.

EXOPHARM LIMITED ACN: 163 765 991 ASX:EX1 Address: Level 17, 31 Queen Street Melbourne 3000 Telephone: 03 9111 0026 Email: info@exopharm.com Web: www.exopharm.com